Compare Fortune Mate Indonesia Tbk (FMII) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortune Mate Indonesia Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Fortune Mate Indonesia Tbk trades at Rp254 (market cap 1.63T, 5.8K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Fortune Mate Indonesia Tbk is far larger — about 15.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| FMII | SCPI | |
|---|---|---|
Market Cap | 1.63T | 104.4B |
Volume | 5.8K | — |
Lot | 58 | — |
Turnover | 1.45M | — |
Average Price | 249.52 | — |
Value | 1.45M | — |
Indicative Equilibrium Price | 254 | — |
Indicative Equilibrium Volume | 1 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortune Mate Indonesia Tbk
PT Fortune Mate Indonesia Tbk (the Entity) was established within the framework of the Foreign Capital Investment Law (PMA) No. 1 year 1967 based on Notarial Deed No. 44 dated June 24, 1989 by Rika You Soo Shin, S.H., notary in Surabaya. The Entity has started its commercial operations since 1989 comprises the manufacturing of footwear were located in Sidoarjo, East Java and stopped its operation since middle of March 2004. The Entity's office and real estate are located in Surabaya.
Read more on FMII →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
